Argenica Therapeutics Ltd (AU:AGN)
ASX:AGN
Want to see AU:AGN full AI Analyst Report?
AGN Stock Chart & Stats
AU$0.18
<AU$0.01(0.81%)
At close: 4:00 PM EST
AU$0.18
<AU$0.01(0.81%)
Day’s Range― - ―
52-Week RangeAU$0.11 - AU$0.79
Previous CloseN/A
Volume9.34K
Average Volume (3M)511.75K
Market Cap
AU$14.13M
Enterprise ValueAU$9.09M
Total Cash (Recent Filing)AU$10.56M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Mar 02, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding128,456,710
10 Day Avg. Volume288,263
30 Day Avg. Volume511,745
Financial Highlights & Ratios
PEG Ratio-2.24
Price to Book (P/B)13.39
Price to Sales (P/S)30.16
P/FCF Ratio-16.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.1
Revenue Forecast (FY)AU$27.40M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetNo reported debt provides durable solvency and financing flexibility for a development-stage biotech. This reduces near-term bankruptcy risk and preserves capacity to structure non-debt financing (grants, equity, licensing), supporting sustained R&D investment without interest burden.
Revenue ScalingYear-over-year revenue growth demonstrates emerging commercial or grant traction for the pipeline. For a small biotech, rising revenues improve credibility with partners and investors, help extend runway if sustained, and indicate that development activities are translating into measurable external support.
Focused Pipeline On Unmet NeedA single, clearly targeted program addressing stroke neuroprotection is a durable strategic strength: large unmet clinical need, strong licensing potential, and clear clinical endpoints. A focused pipeline lets management concentrate resources and pursue partnerships or milestone-driven funding.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flows mean the business cannot self-fund development. Over the next 2–6 months this structural cash burn necessitates new financing or partnerships, creating dilution risk and potential delays to clinical timelines if capital is constrained.
Deepening Losses & Negative MarginsWidening net losses and severely negative margins reflect R&D and operating costs far outstripping revenue. This undermines long-term self-sufficiency, compresses returns on equity, and elevates dependency on external capital unless a clinical or commercial inflection reverses the trend.
Shrinking Equity BaseA halved equity base materially reduces the financial buffer against setbacks and signals prior dilution or accumulated losses. With ongoing negative cash flow, the company faces heightened fundraising likelihood, increasing dilution risk and governance pressure on strategic choices.
Argenica Therapeutics Ltd News
AGN FAQ
What was Argenica Therapeutics Ltd’s price range in the past 12 months?
Argenica Therapeutics Ltd lowest share price was AU$0.10 and its highest was AU$0.79 in the past 12 months.
What is Argenica Therapeutics Ltd’s market cap?
Argenica Therapeutics Ltd’s market cap is AU$14.13M.
When is Argenica Therapeutics Ltd’s upcoming earnings report date?
Argenica Therapeutics Ltd’s upcoming earnings report date is Mar 02, 2027 which is in 254 days.
How were Argenica Therapeutics Ltd’s earnings last quarter?
Argenica Therapeutics Ltd released its earnings results on Feb 10, 2026. The company reported -AU$0.03 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.03.
Is Argenica Therapeutics Ltd overvalued?
According to Wall Street analysts Argenica Therapeutics Ltd’s price is currently Overvalued.
Does Argenica Therapeutics Ltd pay dividends?
Argenica Therapeutics Ltd does not currently pay dividends.
What is Argenica Therapeutics Ltd’s EPS estimate?
Argenica Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Argenica Therapeutics Ltd have?
Argenica Therapeutics Ltd has 128,456,710 shares outstanding.
What happened to Argenica Therapeutics Ltd’s price movement after its last earnings report?
Argenica Therapeutics Ltd reported an EPS of -AU$0.03 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.754%.
Which hedge fund is a major shareholder of Argenica Therapeutics Ltd?
Currently, no hedge funds are holding shares in AU:AGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Argenica Therapeutics Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.48%
12-Months-Change
Fundamentals
Return on Equity
-183.51%
Trailing 12-Months
Asset Growth
-66.25%
Trailing 12-Months
Company Description
Argenica Therapeutics Ltd
Argenica Therapeutics Limited is an Australian entity dedicated to the research and development of a therapeutic neuroprotective medication. Its leading investigational drug, ARG-007, is a peptide designed to safeguard brain cells and reduce neuronal death following a stroke or various other neurological injuries. This company was established in 2019 and operates out of Nedlands, Australia.
Technical Analysis
Alterity Therapeutics
―
Race Oncology Ltd.
―
Nanollose Ltd.
―
Avecho Biotechnology Limited
―
AdAlta Ltd.
―
Options Prices
Currently, No data available
---